| Project/Area Number |
18K08164
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 53030:Respiratory medicine-related
|
|---|
| Research Institution | Asahikawa Medical College |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2020: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2019: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | NUT midline carcinoma / NUT carcinoma / miR-21 / microRNA / Nut midline carcinoma / miRNA |
|---|
| Outline of Final Research Achievements |
NUT midline carcinoma is a rare but highly malignant tumor with a poor prognosis. It is often found as an incurable advanced cancer, but there is no effective and established treatment. In this study, we analyzed microRNAs as a new therapeutic target for nut midline calcium. From the results of our microRNA analysis, a microRNA called miR-21 was identified as a candidate therapeutic target. When the function of miR-21 was evaluated in an experiment using a cell line, an inhibitor of miR-21 was effective for NUT midline carcinoma.
|
| Academic Significance and Societal Importance of the Research Achievements |
現在、ナットミッドラインカルシノーマに対する有効な治療薬が無いが、我々が行った研究の結果、miR-21阻害剤がナットミッドラインカルシノーマに対して有効な治療薬である可能性が示された。今後、前臨床試験でこの阻害剤の効果をさらに評価することにより、予後不良な疾患であるナットミッドラインカルシノーマの新たな治療法として臨床応用できる期待がある。
|
